Back to results
US 8,895,777 B2Granted
Compounds and compositions for delivering active agents
AssigneeEmisphere Technologies, Inc.
InventorsJun Liao, Pingwah Tang, David Gschneidner, Jonathan Maeyer
Life of this patent
Estimating the term…
Abstract
The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents.
Claims23
A delivery agent compound selected from the group consisting of:
- and pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising
- (A) a therapeutically effective amount of a biologically active agent;
- (B) at least one compound selected from the group consisting of
- and pharmaceutically acceptable salts thereof, and
- (C) a pharmaceutically acceptable excipient,
- wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban;
- and any combination thereof.
3 more elements
A pharmaceutical composition comprising
- (A) a therapeutically effective amount of a biologically active agent;
- (B) a compound selected from:
- and pharmaceutically acceptable salts thereof;
- and
- (C) a pharmaceutically acceptable excipient;
- wherein the biologically active agent is selected from calcitonin, insulin, GLP-1, heparin, argatroban, and any combination thereof.
3 more elements
A pharmaceutical composition comprising
- (A) a therapeutically effective amount of a biologically active agent;
- (B) a compound selected from:
- and pharmaceutically acceptable salts thereof;
- and
- (C) a pharmaceutically acceptable excipient;
- wherein the biologically active agent is selected from calcitonin, insulin, GLP-1, heparin, argatroban;
- and any combination thereof.
4 more elements
A pharmaceutical composition comprising
- (A) a therapeutically effective amount of a biologically active agent;
- (B) a compound selected from:
- and pharmaceutically acceptable salts thereof;
- and
- (C) a pharmaceutically acceptable excipient;
- wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban;
- and any combination thereof.
4 more elements
A pharmaceutical composition comprising
- (A) a therapeutically effective amount of a biologically active agent;
- (B) a compound selected from:
- and pharmaceutically acceptable salts thereof;
- and
- (C) a pharmaceutically acceptable excipient;
- wherein the biologically active agent is selected from BIBN-4096BS, growth hormone releasing factor, interferons, interleukin-1, interleukin-2, insulin, insulin-like growth factor (IGF), heparin, heparinoids, dermatans, chondroitins, calcitonin, erythropoietin (EPO), atrial naturetic factor, CPHPC, monoclonal antibodies, somatostatin, octreotide, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim, GM-CSF5, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, gallium nitrate, glucagon, DPP-4 inhibitors, peptide YY, desferoxamine (DFO), parathyroid hormone (PTH), glucagon-like peptide 1 (GLP-I), argatroban;
- and any combination thereof.
4 more elements
Dependencies are inferred from the claim text.